Virax Biolabs Group Ltd VRAX

Healthcare SIC 2835 - In Vitro & In Vivo Diagnostic Substances NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2026FY2024FY2023FY2022FY2021FY2020FY2019
Operating income —-$6.2M-$6.5M-$5.7M-$1.7M-$644.5K—
Net income —-$6.1M-$6.7M-$5.5M-$1.7M-$672.9K—

Balance sheet

Fiscal year FY2026FY2024FY2023FY2022FY2021FY2020FY2019
Total assets —$6.4M$5.5M$9.8M$48.7K$39.6K—
Total equity —$5.5M$5.1M$8.9M-$1.2M-$831.8K-$1.2M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-295158.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
Operating income by fiscal year, in US dollars The same figures are in the table below this chart. -8M -6M -4M -2M 0 Operating income, FY2020: -644.5K Operating income, FY2021: -1.7M Operating income, FY2022: -5.7M Operating income, FY2023: -6.5M Operating income, FY2024: -6.2M FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2026
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2026
Operating income — -$644.5K -$1.7M -$5.7M -$6.5M -$6.2M —

Others in SIC 2835

TickerCompanyMarket capP/ERevenue growth
IDXX IDEXX LABORATORIES INC /DE $42.18B 40.9x 10.4%
LNTH Lantheus Holdings, Inc. $6.59B 29.6x 0.5%
CLDX Celldex Therapeutics, Inc. $3.12B — -78.0%
NEOG NEOGEN CORP $2.58B — -2.7%
NTLA Intellia Therapeutics, Inc. $1.79B — 16.9%
QDEL QuidelOrtho Corp $958.0M — -1.9%
ACHV ACHIEVE LIFE SCIENCES, INC. $873.6M — —
TKNO Alpha Teknova, Inc. $371.5M — 7.4%